An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey

被引:37
作者
Caglayan, Derya [1 ]
Suner, Ahmet F. [2 ]
Siyve, Neslisah [2 ]
Guzel, Irmak [3 ]
Irmak, Caglar [4 ]
Isik, Elif [2 ]
Appak, Ozgur [3 ]
Celik, Muammer [4 ]
Ozturk, Gamze [3 ]
Cavus, Sema Alp [3 ]
Ergor, Gul [1 ]
Sayiner, Arzu [3 ]
Ergor, Alp [2 ]
Demiral, Yucel [2 ]
Kilic, Bulent [2 ]
机构
[1] Dokuz Eylul Univ, Sch Med, Dept Publ Hlth, Div Epidemiol, TR-35220 Izmir, Turkey
[2] Dokuz Eylul Univ, Sch Med, Dept Publ Hlth, Izmir, Turkey
[3] Dokuz Eylul Univ, Sch Med, Dept Med Microbiol, Izmir, Turkey
[4] Dokuz Eylul Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Izmir, Turkey
关键词
antibody; BNT162b2; CoronaVac; heterologous vaccination; SARS-CoV-2;
D O I
10.1002/jmv.27620
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Limited data are available on the short- to midterm levels of antibodies to the CoronaVac vaccine and quantitative change in humoral response after homologous or heterologous booster doses. In this prospective cohort study, we evaluated the anti-receptor-binding domain (RBD) immunoglobulin G (IgG) levels after two doses of CoronaVac and heterologous/homologous booster administration among healthcare workers in a university hospital in Turkey. Quantitative anti-RBD IgG antibody levels were measured at first and fourth months in 560 healthcare workers who had completed two doses of CoronaVac vaccine, and within 2 months after the third dose of CoronaVac or BNT162b2. Participants were asked to complete a questionnaire during the first blood draw. The seropositivity rate was 98.9% and 89.1%, and the median antibody level was 469.2 AU/ml and 166.5 AU/ml at first and fourth month, respectively. In the fourth month, a mean reduction of 61.4% +/- 20% in antibody levels was observed in 79.8% of the participants. The presence of chronic disease (odds ratio [OR]: 1.76, 95% confidence interval [CI]: 1.15-2.69) and being in the 36-50 age group (OR: 2.11, 95% CI: 1.39-3.19) were identified as independent predictors for low antibody response. The antibody level increased 104.8-fold (median: 17 609.4 vs. 168 AU/ml) and 8.7-fold (median: 1237.9 vs. 141.4 AU/ml) in the participants who received BNT162b2 and CoronaVac, respectively. During the follow-up, 25 healthcare workers (4.5%) were infected with severe acute respiratory syndrome coronavirus 2. Considering the waning immunity and circulating variants, a single booster dose of messenger RNA vaccine seems reasonable after the inactivated vaccine especially in risk groups.
引用
收藏
页码:2212 / 2221
页数:10
相关论文
共 32 条
[1]   Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].
Bar-On, Yinon M. ;
Goldberg, Yair ;
Mandel, Micha ;
Bodenheimer, Omri ;
Freedman, Laurence ;
Kalkstein, Nir ;
Mizrahi, Barak ;
Alroy-Preis, Sharon ;
Ash, Nachman ;
Milo, Ron ;
Huppert, Amit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400
[2]  
Bausch D., 2021, COVID 19 WHY WE CANT
[3]   Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers [J].
Bayram, Aysen ;
Demirbakan, Hadiye ;
Gunel Karadeniz, Pinar ;
Erdogan, Merve ;
Kocer, Ipek .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (09) :5560-5567
[4]   To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination [J].
Chiu, Nan-Chang ;
Chi, Hsin ;
Tu, Yu-Kang ;
Huang, Ya-Ning ;
Tai, Yu-Lin ;
Weng, Shun-Long ;
Chang, Lung ;
Huang, Daniel Tsung-Ning ;
Huang, Fu-Yuan ;
Lin, Chien-Yu .
EXPERT REVIEW OF VACCINES, 2021, 20 (10) :1211-1220
[5]   Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection [J].
Dan, Jennifer M. ;
Mateus, Jose ;
Kato, Yu ;
Hastie, Kathryn M. ;
Yu, Esther Dawen ;
Faliti, Caterina E. ;
Grifoni, Alba ;
Ramirez, Sydney, I ;
Haupt, Sonya ;
Frazier, April ;
Nakao, Catherine ;
Rayaprolu, Vamseedhar ;
Rawlings, Stephen A. ;
Peters, Bjoern ;
Krammer, Florian ;
Simon, Viviana ;
Saphire, Erica Ollmann ;
Smith, Davey M. ;
Weiskopf, Daniela ;
Sette, Alessandro ;
Crotty, Shane .
SCIENCE, 2021, 371 (6529) :587-+
[6]   Evidence for antibody as a protective correlate for COVID-19 vaccines [J].
Earle, Kristen A. ;
Ambrosino, Donna M. ;
Fiore-Gartland, Andrew ;
Goldblatt, David ;
Gilbert, Peter B. ;
Siber, George R. ;
Dull, Peter ;
Plotkin, Stanley A. .
VACCINE, 2021, 39 (32) :4423-4428
[7]   Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status [J].
Eyre, David W. ;
Lumley, Sheila F. ;
Wei, Jia ;
Cox, Stuart ;
James, Tim ;
Justice, Anita ;
Jesuthasan, Gerald ;
O'Donnell, Denise ;
Howarth, Alison ;
Hatch, Stephanie B. ;
Marsden, Brian D. ;
Jones, E. Yvonne ;
Stuart, David, I ;
Ebner, Daniel ;
Hoosdally, Sarah ;
Crook, Derrick W. ;
Peto, Tim E. A. ;
Walker, Timothy M. ;
Stoesser, Nicole E. ;
Matthews, Philippa C. ;
Pouwels, Koen B. ;
Walker, A. Sarah ;
Jeffery, Katie .
CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) :1516.e7-1516.e14
[8]   Antibody titres decline 3-month post-vaccination with BNT162b2 [J].
Favresse, Julien ;
Bayart, Jean-Louis ;
Mullier, Francois ;
Elsen, Marc ;
Eucher, Christine ;
Van Eeckhoudt, Sandrine ;
Roy, Tatiana ;
Wieers, Gregoire ;
Laurent, Christine ;
Dogne, Jean-Michel ;
Closset, Melanie ;
Douxfils, Jonathan .
EMERGING MICROBES & INFECTIONS, 2021, 10 (01) :1495-1498
[9]   Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection [J].
Feng, Shuo ;
Phillips, Daniel J. ;
White, Thomas ;
Sayal, Homesh ;
Aley, Parvinder K. ;
Bibi, Sagida ;
Dold, Christina ;
Fuskova, Michelle ;
Gilbert, Sarah C. ;
Hirsch, Ian ;
Humphries, Holly E. ;
Jepson, Brett ;
Kelly, Elizabeth J. ;
Plested, Emma ;
Shoemaker, Kathryn ;
Thomas, Kelly M. ;
Vekemans, Johan ;
Villafana, Tonya L. ;
Lambe, Teresa ;
Pollard, Andrew J. ;
Voysey, Merryn .
NATURE MEDICINE, 2021, 27 (11) :2032-+
[10]  
Gilbert Peter B, 2022, Science, V375, P43, DOI [10.1101/2021.08.09.21261290, 10.1126/science.abm3425]